Stock News

Evoke Pharma Provides Clinical Program Update For EVK-001

Evoke (NASDAQ:EVOK) issued a press release today to provide an update on its clinical program for EVK-001, a novel metoclopramide nasal spray for the relief of …

Acorda Therapeutics: rHIgM22 Appears Safe In Multiple Sclerosis

Acorda Therapeutics (NASDAQ:ACOR) announced this morning the safety and tolerability data from its Phase 1 clinical trial of rHIgM22, a remyelinating antibody, which is …

GERN: Geron to Present at the 17th Annual BIO CEO & Investor Conference

MENLO PARK, Calif., February 2, 2015 – Geron Corporation (Nasdaq:GERN) today announced that John Scarlett, M.

SLXP: Salix Announces the Promotion of William P. Forbes, PharmD to President, Medical, R&D and Chief Development Officer

(BUSINESS WIRE)–Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) (“Salix” or the “Company”) today announced the promotion of William P.

Stock Update (NASDAQ: AAL): American Airlines Pilots Approve Contract

The Allied Pilots Association (APA), representing 15,000 pilots at American Airlines (NASDAQ: AAL), announced today its members have approved a new five-year contract …

pSivida Corp. Announces Second Quarter Fiscal Year 2015 Financial Results Release Date and Conference Call Information

(BUSINESS WIRE)– pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced …

Micron Prices $1 Billion Offering of 5.25% Senior Notes

Micron Technology, Inc., (Nasdaq:MU) today announced the pricing of an offering of $1 billion aggregate principal amount of its 5.

Medivation Reports Third Quarter Financial Results and Provides Corporate Update

(Marketwired) – 11/06/14 – Medivation, Inc. (NASDAQ:MDVN) today reported its financial results for the third quarter ended September 30, 2014.

Stock Update (NASDAQ:ICPT): Intercept Receives Breakthrough Therapy Designation From FDA

Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), today announced that its investigational product obeticholic acid (OCA) has received “breakthrough therapy designation” from the U.

Exelixis to Present at the Leerink Global Healthcare Conference

(BUSINESS WIRE)–Jan. 29, 2015– Exelixis, Inc.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts